NYSEAMERICAN : PLX
Protalix BioTherapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.59 USD (Oct 30, 2026, 10:12 AM EDT) · Market cap 208.68M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 207.87M |
| Enterprise Value | 176.43M |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 80.57M |
| Shares Outstanding | 80.57M |
| Shares Change (YoY) | -2.61% |
| Shares Change (QoQ) | -0.59% |
| Owned by Insiders (%) | 3.88% |
| Owned by Institutions (%) | 24.64% |
| Float | 77.45M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 10.91 |
| Forward PE | n/a |
| PS Ratio | 2.57 |
| Forward PS | 3.37 |
| PB Ratio | 2.92 |
| P/TBV Ratio | 2.91 |
| P/FCF Ratio | 27.06 |
| P/OCF Ratio | 20.91 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 9.29 |
| EV / Sales | 2.18 |
| EV / EBITDA | 7.08 |
| EV / EBIT | 7.56 |
| EV / FCF | 22.96 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.94 |
| Quick Ratio | 1.82 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 0.34 |
| Debt / FCF | 1.20 |
| Interest Coverage | 18.97 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 31.23% |
| Return on Assets (ROA) | 15.42% |
| Return on Invested Capital (ROIC) | 58.24% |
| Return on Capital Employed (ROCE) | 29.50% |
| Weighted Average Cost of Capital (WACC) | 4.43% |
| Revenue Per Employee | $356,721 |
| Profits Per Employee | $83,827 |
| Employee Count | 226 |
| Asset Turnover | 0.85 |
| Inventory Turnover | 1.64 |
Taxes
| Measure | Value |
|---|
| Income Tax | 4.52M |
| Effective Tax Rate | 19.26% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.02 |
| 52-Week Price Change | +8.65% |
| 50-Day Moving Average | 2.65 |
| 200-Day Moving Average | 2.42 |
| Relative Strength Index (RSI) | 46.18 |
| Average Volume (20 Days) | 730,307 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.51M |
| Short Previous Month | 2.88M |
| Short % of Shares Out | 4.35% |
| Short % of Float | 4.53% |
| Short Ratio (days to cover) | 3.96 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 80.62M |
| Gross Profit | 36.90M |
| Operating Income | 23.29M |
| Pretax Income | 23.46M |
| Net Income | 18.95M |
| EBITDA | 24.86M |
| EBIT | 23.29M |
| Earnings Per Share (EPS) | $0.24 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 40.66M |
| Total Debt | 9.21M |
| Net Cash | 31.45M |
| Net Cash Per Share | $0.39 |
| Equity (Book Value) | 71.40M |
| Book Value Per Share | 0.89 |
| Working Capital | 60.83M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 9.92M |
| Capital Expenditures | -2.26M |
| Depreciation & Amortization | 1.57M |
| Net Borrowing | n/a |
| Free Cash Flow | 7.67M |
| FCF Per Share | $0.10 |
Margins
| Measure | Value |
|---|
| Gross Margin | 45.77% |
| Operating Margin | 28.89% |
| Pretax Margin | 29.10% |
| Profit Margin | 23.50% |
| EBITDA Margin | 30.84% |
| EBIT Margin | 28.89% |
| FCF Margin | 9.51% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 2.61% |
| Shareholder Yield | 2.61% |
| Earnings Yield | 9.16% |
| FCF Yield | 3.70% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 9.28% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Dec 20, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.03 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |